GRTXD (Galera Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRTXD Galera Therapeutics Inc GRTXD
35 GF Score
Price $16.39
! 2 Warning Signs
View Full Analysis

What is Galera Therapeutics Net Margin %?

Galera Therapeutics GRTXD -1.02% 35 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates GRTXD with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 941 Biotechnology companies, Galera Therapeutics ranks worse than 106269.82% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Galera Therapeutics's Net Income for the three months ended in Mar. 2026 was $-1.61 Mil. Galera Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Galera Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Galera Therapeutics's Net Margin % or its related term are showing as below:


GRTXD's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Galera Therapeutics  (OTCPK:GRTXD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Galera Therapeutics Net Margin % Related Terms

Galera Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Galera Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galera Therapeutics Net Margin % Chart

Galera Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Galera Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GRTXD vs CELU, BCDA, KTTA: Net Margin % Comparison

For the Biotechnology subindustry, Galera Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galera Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's Net Margin % falls into.


GRTXD
35GF Score
Galera Therapeutics Inc GRTXD
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galera Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Galera Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=149.049/0
= %

Galera Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.606/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Galera Therapeutics (GRTXD) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Galera Therapeutics and its competitors. According to the industry distribution chart, Galera Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is Galera Therapeutics' Net Margin % too high?
Galera Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Galera Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Galera Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Galera Therapeutics' Net Margin % compare to CELU and BCDA?
According to the Biotechnology industry distribution chart, Galera Therapeutics ranks #999999 out of 941 companies for Net Margin %. This places Galera Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Galera Therapeutics and its competitors. Galera Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galera Therapeutics stock overvalued right now?
Galera Therapeutics (GRTXD) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Galera Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Galera Therapeutics (GRTXD), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galera Therapeutics Business Description

Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion.
35GF Score

Get the complete analysis for GRTXD

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.39
Price